-
Loading metrics
Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613
- Moises O. Guardado Rivas,
- Shawn D. Stuart,
- Daniel Thach,
- Michael Dahan,
- Robert Shorr,
- Zuzana Zachar,
- Paul M. Bingham
x
- Published: June 8, 2022
- https://doi.org/10.1371/journal.pone.0269620